Breaking News Instant updates and real-time market news.

M

Macy's

$20.80

-2.232 (-9.69%)

, KSS

Kohl's

$39.12

-2.81 (-6.70%)

12:08
08/10/17
08/10
12:08
08/10/17
12:08

On The Fly: Top stock stories at midday

Stocks began the day deep in negative territory as investors moved to the sideline as tensions between North Korea and the U.S. have escalated over the last three days. The averages have moved in a narrow range since the open but are near their lows at midday. ECONOMIC EVENTS: In the U.S., initial jobless claims rose 3,000 to 244,000 in the first week of August, reversing a 5,000 drop in the prior week to leave a fairly neutral start for the month. The Producer Price Index dipped 0.1% in July, missing expectations for a 0.1% increase, while the core PPI also slid 0.1%, versus expectations for a 0.2% increase. COMPANY NEWS: Shares of Macy's (M) dropped 9% after the biggest U.S. department store operator by sales announced better than expected top and bottom line results but reported another decline in comparable sales, marking the tenth straight quarter of decline for that closely watched measure. Macy's president and CEO Jeff Gennette said the second quarter results were in line with the company's expectations, leaving it on track to meet 2017 sales and earnings guidance, adding that the company expects the launch of its new loyalty program and marketing strategy to "further improve our sales trend in the back half of the year." Also lower was department store peer Kohl's (KSS), which fell 6% despite reporting adjusted quarterly profits that beat expectations. MAJOR MOVERS: Among the notable gainers was Perrigo (PRGO), which rallied 16% after its earnings and outlook beat expectations on the heels of several of the other companies in the generics space, headlined by Mylan (MYL) and Teva (TEVA), having recently lowered their own guidance. Also higher following its earnings report was Hudson Technologies (HDSN), which rose 19%. The company also announced a deal to buy Airgas-Refrigerants, a subsidiary of Airgas, which Craig-Hallum analyst Steven Dyer called a "transformative acquisition." Among the noteworthy losers was Blue Apron (APRN), which dropped 15% after the meal kit company reported its first quarterly results since its initial public offering. Also lower following their earnings reports were Chicago Bridge & Iron (CBI) and e.l.f. Beauty (ELF). INDEXES: Near midday, the Dow was down 137.93, or 0.63%, to 21,910.77, the Nasdaq was down 101.74, or 1.6%, to 6,250.59, and the S&P 500 was down 25.41, or 1.03%, to 2,448.61.

M

Macy's

$20.80

-2.232 (-9.69%)

KSS

Kohl's

$39.12

-2.81 (-6.70%)

PRGO

Perrigo

$78.69

12.32 (18.56%)

APRN

Blue Apron

$5.28

-0.965 (-15.46%)

MYL

Mylan

$32.08

0.29 (0.91%)

TEVA

Teva

$17.75

0.245 (1.40%)

HDSN

Hudson Technologies

$7.96

-0.07 (-0.87%)

CBI

CB&I

$11.05

-5.28 (-32.33%)

ELF

e.l.f. Beauty

$24.10

-1.07 (-4.25%)

  • 10

    Aug

  • 10

    Aug

  • 10

    Aug

  • 10

    Aug

  • 30

    Aug

  • 03

    Sep

  • 08

    Sep

  • 09

    Oct

  • 09

    Nov

M Macy's
$20.80

-2.232 (-9.69%)

06/21/17
GDHS
06/21/17
NO CHANGE
GDHS
Nike-Amazon pact yet another department store headwind, says Gordon Haskett
Gordon Haskett analyst noted the reports of Nike (NKE) nearing a deal to sell directly on Amazon (AMZN), which he said wouldn't impact trends overnight but would represent another headwind for department stores, particularly J.C. Penney (JCP) and Kohl's (KSS), where the brand has a larger penetration than at Macy's (M) and Nordstrom (JWN). He keeps an Accumulate rating on Nordstrom, a Hold rating on Macy's and Reduce rating on both J.C. Penney and Kohl's.
06/07/17
GSCO
06/07/17
NO CHANGE
Target $25
GSCO
Neutral
Macy's price target lowered to $25 from $28 at Goldman Sachs
Goldman analyst Lindsay Drucker Mann lowerd Macy's price target to $25 from $28 to reflect weaker margin trends and operating earnings following the company's Investor Day. The analyst is encouraged by the detail around strategic initiatives and has confidence in -3-4% FY17 comp guidance range. Shares are Neutral rated.
05/12/17
COWN
05/12/17
NO CHANGE
Target $29
COWN
Market Perform
Macy's financial modeling worrisome, says Cowen
Cowen analyst Oliver Chen said the rapid transformation of consumers' shopping preferences presents ongoing challenges to Macy's and other retailers. He said the company needs to reinvent promotional techniques that currently are yielding poor store traffic and higher markdowns. Chen said from a financial modeling perspective he is worried, leading him to maintain his Market Perform rating on Macy's shares and cut his price target to $29 from $44.
05/12/17
SBSH
05/12/17
NO CHANGE
Target $23
SBSH
Neutral
Macy's price target lowered to $23 from $30 at Citi
Citi analyst Paul Lejuez lowered his price target for Macy's to $23 saying the company's results yesterday "stood out as extremely weak" amid disappointing quarters across the sector. The analyst keeps a Neutral rating on the shares.
KSS Kohl's
$39.12

-2.81 (-6.70%)

08/10/17
GDHS
08/10/17
UPGRADE
GDHS
Hold
Kohl's upgraded to Hold from Reduce at Gordon Haskett
Gordon Haskett upgraded Kohl's to Hold saying earnings downside looks limited post today's results. The firm raised its price target for the shares to $37 from $36.
08/10/17
JEFF
08/10/17
NO CHANGE
JEFF
Kohl's shares defended at Jefferies
08/08/17
OTRG
08/08/17
UPGRADE
OTRG
Mixed
Kohl's upgraded to Mixed from Negative at OTR Global
OTR Global raised its view on Kohl's to Mixed following checks that indicate Q2 sell-through at least met its plan with most vendors surveyed.
08/02/17
08/02/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wal-Mart (WMT) initiated with an Outperform at Oppenheimer. 2. Kohl's (KSS) assumed with a Buy at Jefferies. 3. Jabil Circuit (JBL) initiated with an Overweight at JPMorgan. 4. Bank of the Ozarks (OZRK) initiated with an Overweight at Morgan Stanley. 5. Sequans (SQNS) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PRGO Perrigo
$78.69

12.32 (18.56%)

06/05/17
RBCM
06/05/17
DOWNGRADE
RBCM
Underperform
Perrigo downgraded to Underperform from Sector Perform at RBC Capital
06/05/17
RBCM
06/05/17
DOWNGRADE
RBCM
Underperform
Perrigo downgraded on multiple headwinds at RBC Capital
As noted earlier, RBC Capital downgraded Perrigo to Underperform from Sector Perform. Analyst Randall Stanicky says that the growth rate of the company's U.S. consumer business "has structurally re-rated lower" amid pricing headwinds and share losses. He adds that the pressures facing the company's generic business will intensify, while its EBITDA growth will be "limited" and it will have difficulty meeting its lowered, 2%-4% revenue growth target. Price target to $60 from $66.
06/05/17
06/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Sector Weight from Overweight at Pacific Crest with analyst Andy Hargreaves saying upside from the launch of iPhone 8 is already reflected in the shares. An "extremely strong iPhone 8 cycle" is being priced into the stock while little weight is being given to gross margins, supply issues, or the likelihood for declines beyond the iPhone 8, Hargreaves tells investors in a research note. 2. Perrigo (PRGO) downgraded to Underperform from Sector Perform at RBC Capital with analyst Randall Stanicky saying the growth rate of the company's U.S. consumer business "has structurally re-rated lower" amid pricing headwinds and share losses. 3. Endocyte (ECYT) downgraded to Neutral from Outperform at Wedbush and to Market Perform from Outperform at Cowen. 4. Affiliated Managers (AMG) was downgraded to Neutral from Buy at Citi while Federated Investors (FII) was downgraded to Sell from Neutral. 5. Veeva (VEEV) downgraded to Equal Weight from Overweight at Morgan Stanley with the firm's analyst saying the 60%+ move in shares year-to-date captures much of the near-term upside in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/16/17
CANT
06/16/17
INITIATION
Target $85
CANT
Overweight
Perrigo initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Perrigo with an Overweight rating and $85 price target.
APRN Blue Apron
$5.28

-0.965 (-15.46%)

08/04/17
STFL
08/04/17
NO CHANGE
STFL
Buy
Blue Apron not cutting staff levels, says Stifel
Stifel said Blue Apron is not cutting staff levels, but shifting its operations to the new Linden, NJ site later this year as part of a planned fulfillment-center migration process.
07/25/17
RHCO
07/25/17
INITIATION
Target $12
RHCO
Buy
Blue Apron initiated with a Buy at SunTrust
SunTrust analyst Youssef Squali initiated Blue Apron with a Buy and a $12 price target citing its leadership position in the emerging meal kit market and attractive valuation. The analyst is positive on Blue Apron's early levels of market penetration, sole focus on the meal-kit market and quality obsession, and strong management team.
07/25/17
SBSH
07/25/17
INITIATION
Target $10
SBSH
Buy
Blue Apron initiated with a Buy at Citi
Citi analyst Mark May started Blue Apron with a Buy rating and $10 price target. The online meal-kit market will likely produce one or two companies that scale over the next 10 years, May tells investors in a research note. He believes the shares could reach $10 over the next year if execution is "solid."
07/25/17
07/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Blue Apron (APRN) was initiated with a Buy at Citi and SunTrust. 2. Blue Buffalo Pet Products (BUFF) initiated with a Neutral at Baird 3. e.l.f. Beauty (ELF) initiated with a Buy at Citi. 4. Grainger (GWW) initiated with a Neutral at Northcoast. 5. Western Asset Mortgage (WMC) initiated with a Market Perform at JMP Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MYL Mylan
$32.08

0.29 (0.91%)

08/09/17
BMOC
08/09/17
NO CHANGE
BMOC
Outperform
Mylan generic push outs 'disappointing, but not surprising,' says BMO Capital
BMO Capital analyst Gary Nachman said expectations for Mylan have been "very low" even before the company reported on its "challenging" second quarter. While the push out of generic Advair and Copaxone into 2018 is a disappointment, he believes this possibility has been the consensus view among investors. Nachman maintains an Outperform rating on Mylan shares.
08/09/17
WELS
08/09/17
NO CHANGE
Target $30
WELS
Market Perform
Mylan results, outlook confirm cautious stance on generics, says Wells Fargo
Wells Fargo analyst David Maris, who notes that he was cautious on the generic sector heading into Mylan's quarterly report, said the results and outlook communicated by the company have confirmed his caution. Maris, who lowered his 2017 and 2018 estimates for Mylan after the company cut its guidance and said they have elected to defer all major U.S. launches from their FY17 financial view, lowered his price target on the stock to $30 from $34.50. He keeps a Market Perform rating on Mylan.
08/09/17
RAJA
08/09/17
NO CHANGE
RAJA
Mylan shares more than reflect reset expectations, says Raymond James
Raymond James believes Mylan shares more than adequately reflect the magnitude of reset expectations and is confident, if management can gain confidence in revised 2018 earnings guidance, the stock can quickly bounce back to the mid-$30 range.
08/10/17
COWN
08/10/17
NO CHANGE
Target $30
COWN
Market Perform
Cowen recommends investors seek better alternatives to Mylan
Cowen analyst Ken Cacciatore updated his Mylan model following underwhelming Q2 results. The analyst noted management lowered guidance meaningfully to reflect current operations. He said he has little faith in the company's ability to get complex products approved or make favorable operational and business development decisions and thus recommend investors look for better alternatives. Cacciatore maintained his Market Perform rating and lowered his price target to $30 from $43 on Mylan shares.
TEVA Teva
$17.75

0.245 (1.40%)

08/04/17
08/04/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Fluor (FLR) was downgraded to Hold from Buy at Deutsche Bank and to Neutral from Buy at DA Davidson. 2. Teva (TEVA) was downgraded to Market Perform from Outperform at Cowen, to Neutral from Outperform at Credit Suisse, and to Underperform from Outperform at RBC Capital. 3. Ford (F) downgraded to Neutral from Buy at Nomura Instinet with analyst Anindya Das citing uncertainties surrounding North America and European growth. 4. Avon Products (AVP) downgraded to Hold from Buy at Deutsche Bank with analyst Faiza Alwy saying the Chief Executive Officer change suggests that a business recovery, should there be one, is more than 12 months away. 5. CommScope (COMM) was downgraded to Hold from Buy at Cross Research, to Neutral from Buy at Longbow, and to Equal Weight from Overweight at Barclays. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/17
MSCO
08/07/17
DOWNGRADE
MSCO
Underweight
Teva downgraded to Underweight from Equal Weight at Morgan Stanley
08/07/17
MSCO
08/07/17
DOWNGRADE
Target $16
MSCO
Teva downgraded to Underweight, bear case target $9 at Morgan Stanley
As previously reported, Morgan Stanley downgraded Teva to Underweight from Equal Weight and cut its price target to $16 from $36. Analyst David Risinger said he underappreciated generic pricing pressure risks on Teva's dividend and expects declining earnings power, combined with high leverage equal to result in a longer recovery. He expects core business generic headwinds and Copaxone generic competition to pressure Teva's long-term earnings power and cut his 2017 earnings estimate to $1.24 from $1.55, 2018 earnings estimate to $4.14 from $4.56, and 2019 earnings estimate to $3.79 from $4.50. Risinger's bear case price target on Teva is $9, which assumes much more severe Copaxone erosion and generic business downside.
08/07/17
08/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Teva (TEVA) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he underappreciated generic pricing pressure risks on Teva's dividend and expects declining earnings power, combined with high leverage equal to result in a longer recovery. 2. Cummins (CMI) downgraded to Buy from Conviction Buy at Goldman Sachs. 3. RE/MAX Holdings (RMAX) downgraded to Equal Weight from Overweight at Stephens. 4. Intrepid Potash (IPI) downgraded to Sell from Neutral at UBS with analyst John Roberts saying that while bankruptcy risk has been "significantly reduced" since the share count was increased 60% with the March secondary, he remains concerned about the lack of long term growth in non-core income and "still depressed" core potash related income. Roberts cites valuation for his downgrade and raised his price target for Intrepid Potash shares to $2.50 from $2.00. 5. Eaton (ETN) downgraded to In Line from Outperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HDSN Hudson Technologies
$7.96

-0.07 (-0.87%)

03/13/17
RILY
03/13/17
INITIATION
Target $9
RILY
Buy
Hudson Technologies resumed with a Buy at B. Riley
B. Riley analyst Ian Corydon resumed coverage of Hudson Technologies with a Buy rating and $9 price target.
05/16/17
CHLM
05/16/17
NO CHANGE
Target $10
CHLM
Buy
Hudson Tech a likely beneficiary of refrigerant shortages, says Craig-Hallum
Craig-Hallum analyst Steven Dyer said his checks on certain HFC refrigerants indicate recent sharp price increases and his industry sources expect further hikes through the summer as supply shortages persist. Dyer, who sees the recent refrigerants price surge as likely to positively impact Hudson Technologies' revenue and margins, reiterates his Buy rating and $10 price target on the shares.
08/10/17
CHLM
08/10/17
NO CHANGE
Target $10
CHLM
Buy
Hudson Tech acquisition of Airgas-Refrigerants a game changer, says Craig-Hallum
Craig-Hallum analyst Steven Dyer notes that Hudson Technologies (HDSN) delivered "solid" quarterly results and announced a transformative acquisition of Airgas-Refrigerants, a subsidiary of Airgas (ARG). The analyst believes the addition of Airgas will double Hudson Technologies' annual revenue and importantly adds scale, enhances the geographic footprint and customer base, and is expected to be "highly accretive" over time. Given its comparable size and myriad financial and competitive benefits, Dyer believes it could be "a game changer." He reiterates a Buy rating and $10 price target on Hudson Technologies' shares.
CBI CB&I
$11.05

-5.28 (-32.33%)

08/10/17
DBAB
08/10/17
NO CHANGE
Target $21
DBAB
Buy
Deutsche Bank lays out path for CB&I shares getting back near $20
Deutsche Bank analyst Chad Dillard says that while CB&I's Q2 results "disappointed significantly," he sees a "clear path" to the shares trading towards the $20 range again should management execute and avoid further cos overruns. Selling the Technology business for 120% of the company's market value, deleveraging and reducing costs by $100M annually would unlock value, Dillard tells investors in a research note titled "2Q Results, A Tough (and Large) Pill to Swallow." The analyst lowered his price target for CB&I shares to $21 from $25 and maintains a Buy rating on the name. The stock in premarket trading is down 22%, or $3.58, to $12.75.
08/10/17
BARD
08/10/17
NO CHANGE
Target $10
BARD
Neutral
CB&I target cut to $10, cash burn puts balance sheet back in focus, says Baird
Baird analyst Andrew Wittmann said CB&I took significant project charges that, along with further cash burn, prompted immediate actions to avoid balance sheet pressure, which is now back in focus. He sees the cash burn likely continuing with ample risk stemming from further project degradation. Wittmann maintained his Neutral rating and lowered his price target to $10 from $24 on CB&I shares.
08/10/17
DADA
08/10/17
NO CHANGE
DADA
CB&I reported 'dismal' Q2 results, but weakness overdone, says DA Davidson
DA Davidson analyst Brent Thielman says that CB&I reported "dismal" Q2 results, and the analyst slashed his price target on the shares to $25 from $40. However, he still believes that the company's EPS will rise to $4 "over time," and he believes that the weakness in the stock is overdone. Thielman keeps a Buy rating on the shares.
08/10/17
SBSH
08/10/17
NO CHANGE
Target $18
SBSH
Neutral
Citi cuts CB&I target, doesn't see 'big liquidity risk'
Citi analyst Andrew Kaplowitz says the seemingly forced sale of CB&I's Technology business is more concerning than he expected. Cost overruns on two gas plants and two U.S. Gulf coast LNG projects that resulted in $548M charges in the quarter seemed to force the company's hand, Kaplowitz tells investors in a research note. The good news, the analyst writes, it that he doesn't see "big liquidity risk" for CB&I because Technology is a "significantly valuable asset that should have lots of interested buyers." The analyst is concerned, however, that the charges in Q2 are "more the start and not the end" of CB&I's challenges. Kaplowitz lowered his price target for the shares to $18 from $20 and keeps a Neutral rating on the name.
ELF e.l.f. Beauty
$24.10

-1.07 (-4.25%)

08/10/17
JEFF
08/10/17
NO CHANGE
Target $30
JEFF
Buy
e.l.f. Beauty results unlikely to reignite share momentum, says Jefferies
Jefferies analyst Stephanie Wissink says e.l.f. Beauty's Q2 report is likely enough to satisfy current shareholders and revive growth interest, but unlikely to "reignite momentum" in the shares. The analyst keeps a Buy rating on the shares with a $30 price target.
08/10/17
PIPR
08/10/17
NO CHANGE
Target $32
PIPR
Overweight
e.l.f. Beauty gaining share amid industry deceleration, says Piper Jaffray
Piper Jaffray analyst Erinn Murphy says e.l.f. Beauty's sales in Q2 accelerated from Q1 despite ongoing industry deceleration in the category. She believes, however, that new money will wait to see further evidence of sales acceleration into the second half of 2017. The analyst lowered her price target for the shares to $32 from $34 and keeps an Overweight rating on e.l.f.
08/04/17
PIPR
08/04/17
NO CHANGE
Target $34
PIPR
Overweight
e.l.f. started rolling out in Ulta Beauty this week, says Piper Jaffray
Piper Jaffray analyst Erinn Murphy says her store checks indicate e.l.f. Beauty (ELF) started rolling out into 170-190 Ulta Beauty (ULTA) doors earlier this week. The analyst is "optimistic" that this in-store launch can be broader over time. Further, her channel checks in the U.K. indicate "broad strength" of sales at Superdrug. Checks suggest e.l.f.'s distribution growth initiatives remain on track and that it remains a share gainer, Murphy tells investors in a research note. She still sees the company as a potential takeout candidate "with time." The analyst has an Overweight rating on e.l.f. with a $34 price target.

TODAY'S FREE FLY STORIES

MDXG

MiMedx

$16.11

-0.82 (-4.84%)

14:23
08/18/17
08/18
14:23
08/18/17
14:23
Earnings
Breaking Earnings news story on MiMedx »

MiMedx backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

RPM

RPM

$48.24

-0.58 (-1.19%)

14:21
08/18/17
08/18
14:21
08/18/17
14:21
Upgrade
RPM rating change  »

RPM upgraded to Gradually…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$16.11

-0.82 (-4.84%)

14:21
08/18/17
08/18
14:21
08/18/17
14:21
Hot Stocks
MiMedx in pact to divest Stability Biologics, focus on biopharma »

MiMedx Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

$NSD

NASDAQ Market Internals

14:17
08/18/17
08/18
14:17
08/18/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
08/18/17
08/18
14:16
08/18/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRBT

iRobot

$98.82

-3.55 (-3.47%)

14:12
08/18/17
08/18
14:12
08/18/17
14:12
Periodicals
Spruce Point questions iRobot's financial guidance »

Spruce Point Capital says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$16.11

-0.82 (-4.84%)

14:11
08/18/17
08/18
14:11
08/18/17
14:11
Hot Stocks
Breaking Hot Stocks news story on MiMedx »

MiMedx in pact to divest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

GE

General Electric

$24.62

-0.1264 (-0.51%)

14:00
08/18/17
08/18
14:00
08/18/17
14:00
Options
19K GE Oct 27 - Jan 27 call spreads at 20c on ISE »

19K GE Oct 27 - Jan 27…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 02

    Oct

RTNB

root9B Technologies

$0.60

-0.1665 (-21.72%)

14:00
08/18/17
08/18
14:00
08/18/17
14:00
Hot Stocks
Breaking Hot Stocks news story on root9B Technologies »

root9B Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MATX

Matson

$22.53

-6.8159 (-23.22%)

13:56
08/18/17
08/18
13:56
08/18/17
13:56
Hot Stocks
Matson drops after competitor TOTE enters Hawaii trade route »

Matson (MATX), which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$243.52

0.4256 (0.18%)

, SPX

S&P 500

13:51
08/18/17
08/18
13:51
08/18/17
13:51
Periodicals
Breitbart's Pollak tweets '#WAR', after Steve Bannon departs White House »

Senior-editor-at-large…

SPY

SPDR S&P 500 ETF Trust

$243.52

0.4256 (0.18%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEY

KeyCorp

$17.68

-0.115 (-0.65%)

13:50
08/18/17
08/18
13:50
08/18/17
13:50
Options
Short-term call buyers in KeyCorp »

Short-term call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

FB

Facebook

$166.91

-3.09 (-1.82%)

13:46
08/18/17
08/18
13:46
08/18/17
13:46
Hot Stocks
Facebook's Zuckerberg says plans to take two months of paternity leave »

Facebook's Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 24

    Aug

  • 13

    Sep

AMC

AMC Entertainment

$12.53

-0.625 (-4.75%)

13:45
08/18/17
08/18
13:45
08/18/17
13:45
Options
AMC Entertainment call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 14

    Sep

  • 27

    Sep

TEVA

Teva

$17.21

0.11 (0.64%)

13:40
08/18/17
08/18
13:40
08/18/17
13:40
Hot Stocks
Teva announces exclusive launch of generic Axiron in the U.S. »

Teva announced the launch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

LGF.A

Lionsgate

$28.25

0.21 (0.75%)

, LGF.B

Lionsgate

$27.18

0.175 (0.65%)

13:37
08/18/17
08/18
13:37
08/18/17
13:37
Hot Stocks
Box Office Battle: 'Annabelle: Creation' to remain in first place »

The major film release…

LGF.A

Lionsgate

$28.25

0.21 (0.75%)

LGF.B

Lionsgate

$27.18

0.175 (0.65%)

TWX

Time Warner

$101.58

-0.03 (-0.03%)

DIS

Disney

$101.02

-0.36 (-0.36%)

VIA

Viacom

$42.40

1.75 (4.31%)

VIAB

Viacom

$29.21

-0.61 (-2.05%)

FOX

21st Century Fox

$26.89

-0.67 (-2.43%)

FOXA

21st Century Fox

$27.35

-0.64 (-2.29%)

SNE

Sony

$38.85

-0.15 (-0.38%)

CMCSA

Comcast

$40.27

-0.97 (-2.35%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 27

    Sep

  • 29

    Sep

MATX

Matson

$22.40

-6.9536 (-23.69%)

13:29
08/18/17
08/18
13:29
08/18/17
13:29
Upgrade
Matson rating change  »

Matson upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYV

Live Nation

$39.06

0.02 (0.05%)

, FB

Facebook

$166.91

-3.09 (-1.82%)

13:28
08/18/17
08/18
13:28
08/18/17
13:28
Hot Stocks
Live Nation drops sharply after Facebook adding ticket sales »

Shares of Live Nation…

LYV

Live Nation

$39.06

0.02 (0.05%)

FB

Facebook

$166.91

-3.09 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Aug

  • 24

    Aug

  • 13

    Sep

BZUN

Baozun

$33.50

-1.98 (-5.58%)

13:25
08/18/17
08/18
13:25
08/18/17
13:25
Options
Baozun call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

FB

Facebook

$166.91

-3.09 (-1.82%)

, EBAY

eBay

$34.85

-0.51 (-1.44%)

13:20
08/18/17
08/18
13:20
08/18/17
13:20
Periodicals
Facebook adding ticket sales to Marketplace, Recode reports »

Facebook's (FB)…

FB

Facebook

$166.91

-3.09 (-1.82%)

EBAY

eBay

$34.85

-0.51 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 24

    Aug

  • 28

    Aug

  • 29

    Aug

  • 07

    Sep

  • 13

    Sep

PEI

Pennsylvania REIT

$10.11

-0.28 (-2.69%)

, FL

Foot Locker

$34.98

-12.72 (-26.67%)

13:18
08/18/17
08/18
13:18
08/18/17
13:18
Periodicals
Pennsylvania REIT falls after Foot Locker weakness, Bloomberg says »

Shares of Pennsylvania…

PEI

Pennsylvania REIT

$10.11

-0.28 (-2.69%)

FL

Foot Locker

$34.98

-12.72 (-26.67%)

LB

L Brands

$36.28

-1.27 (-3.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

SPX

S&P 500

13:17
08/18/17
08/18
13:17
08/18/17
13:17
Hot Stocks
WH Press Sec.: Kelly, Bannon 'mutually agreed today would be Steve's last day' »

A statement from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
08/18/17
08/18
13:17
08/18/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
08/18/17
08/18
13:16
08/18/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

13:15
08/18/17
08/18
13:15
08/18/17
13:15
Periodicals
Kelly, Bannon 'mutually agreed today would be Steve's last day,' CNBC tweets »

Citing the White House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.